H.C. Wainwright lowered the firm’s price target on Ovid Therapeutics (OVID) to $2 from $3 and keeps a Buy rating on the shares following the Q4 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OVID:
- Applied Therapeutics appoints Baumgartner as Chief Regulatory Officer
- Ovid Therapeutics price target lowered to $3 from $4 at Wedbush
- Ovid Therapeutics’ Cybersecurity Challenges: Navigating IT Risks and Third-Party Dependencies
- Ovid Therapeutics sees cash runway into 2H26
- Ovid Therapeutics reports Q4 EPS (13c), consensus (17c)